NL-OMON32480
Recruiting
Not Applicable
Healthy ageing and intellectual disability - Healthy ageing and intellectual disability
De Bruggen0 sites2,150 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Anxiety and depression. Malnutrition. Inactivity.
- Sponsor
- De Bruggen
- Enrollment
- 2150
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •50 years or over for all parts of research except for the test\-retest reliability research
- •21 tot 50 years for the ca. 60 participants in the test\-retest reliability research.
- •client of one of the four health care organisations
- •informed consent
Exclusion Criteria
- •severely ill
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Healthy ageing and intellectual disabilities (HA-ID) study, the follow-upichamelijke en geestelijke gezondheidsaandoeningen bij mensen met een verstandelijke beperking.Intellectual disability and ageingNL-OMON54642Erasmus MC, Universitair Medisch Centrum Rotterdam271
Recruiting
Not Applicable
Healthy Ageing and Intellectual Disabilities: Ten years later (In dutch: Gezond ouder met een verstandelijke beperking: Tien jaar later)Intellectual disabilityNL-OMON28611Academic Collaborative Center HA-ID, and the Department of General Practice Erasmus MC, University Medical Center Rotterdam212
Completed
Not Applicable
North Health in Intellectual DisabilityIntellectual Disabilities (F70-F79)NCT03889002University Hospital of North Norway214
Completed
Not Applicable
Mental Health and Healthcare in Adults With Intellectual DisabilitiesIntellectual Disabilities (F70-F79)Problem;Behaviour;AdultMental Health IssueEmploymentDelivery of Health CareNCT05703503Norwegian University of Science and Technology214
Completed
Not Applicable
The continuum between healthy ageing and idiopathic Parkinson Disease within a propagation perspective of inflammation and damage: the search for new diagnostic, prognostic and therapeutic targets. Phase 2G20.9DRKS00011260IRCCS Istituto delle Scienze Neurologiche di Bologna345